Premium
Efficacy of ipriflavone and 1α vitamin D therapy for the cessation of vertebral bone loss
Author(s) -
Ushiroyama T.,
Okamura S.,
Ikeda A.,
Ueki M.
Publication year - 1995
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/0020-7292(94)02280-c
Subject(s) - medicine , smoking cessation , vitamin d and neurology , osteoporosis , physical therapy , pathology
Objective: This study investigated whether a combined regimen of ipriflavone and 1α vitamin D is effective in stopping postmenopausal bone loss. Methods: Ninety‐eight postmenopausal women were recruited and randomly assigned to one of four groups: group 1, ipriflavone alone; group 2, 1α vitamin D alone; group 3, combined regimen of ipriflavone and 1α vitamin D; group 4, no treatment. Vertebral bone mineral density, measured by dual energy X‐ray absorptiometry, serum alkaline phosphatase, calcitonin, parathyroid hormone, osteocalcin, urinary calcium and hydroxyproline were measured before and at the 6th, 12th and 18th month of the study. All comparisons were made using Student's t‐test of means. Result: There was a significant reduction in vertebral bone loss in the patients receiving the combined therapy (mean loss after 18 months 0.33% in the combination group vs. 2.37%, 1.15% and 3.70% in the ipriflavone alone, 1α vitamin D alone, and control groups, respectively; P < 0.001). Conclusion: These findings suggest that the combined regimen could prevent postmenopausal bone loss.